LC
MRTX

Lindbrook Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Lindbrook Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-203
Closed -$11.9K – 2784
2023
Q4 		$11.9K Buy
203
+5
+3% +$281 ﹤0.01% 1451
2023
Q3 		$8.63K Sell
198
-105
-35% -$3.75K ﹤0.01% 1491
2023
Q2 		$10.9K Buy
303
+80
+36% +$3.3K ﹤0.01% 1404
2023
Q1 		$8.29K Buy
223
+131
+142% +$5.89K ﹤0.01% 1573
2022
Q4 		$4.17K Sell
92
-79
-46% -$5.11K ﹤0.01% 1914
2022
Q3 		$12K Buy
171
+52
+44% +$3.85K ﹤0.01% 1261
2022
Q2 		$8K Buy
119
+113
+1,883% +$7.19K ﹤0.01% 1378
2022
Q1 		$0 Sell
6
-14
-70% -$1.43K ﹤0.01% 2649
2021
Q4 		$3K Buy
20
+10
+100% +$1.55K ﹤0.01% 1720
2021
Q3 		$2K Buy
10
+7
+233% +$1.13K ﹤0.01% 1642
2021
Q2 		$0 Buy
+3
New +$482 ﹤0.01% 2019
2021
Q1 		– Sell
-9
Closed -$2K – 1959
2020
Q4 		$2K Buy
+9
New +$1.95K ﹤0.01% 1538

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lindbrook Capital's MRTX Position: Q1 2024 in Review

Lindbrook Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 203 shares — an estimated $11.9K sold.

Lindbrook Capital first reported a position in MRTX in Q4 2020 and held it in 12 quarters. The position peaked at $12K in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Lindbrook Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Lindbrook Capital sold 203 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $11.9K.
  • Lindbrook Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • Lindbrook Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $12K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Lindbrook Capital's 13F filing for Q1 2024, filed 25 Apr 2024.